orm PTO-1449				U.S. Department of Commerce Patent and Trademark Office								Atty. Docke 65503-B	,	Serial No. 09/825,682		
	ď.			M	ΓΔΊ	rto						Applicants Elena Fei	nstein and O	rna Mor		
2 1	70U3	NFORMATION DISC BY APPL (Use several shee							PL	ICANT		Filing Date April 4, 2001		Group 1634		
ADE	a con					Ž.					TENT DOCUMENT	S				
amin		Document Number								Date	Name		Subclass Filing Da if Appro			
tial	5/		5 4		2	2	2	4	3	06/06/95	Jalkanen et al.					
1	ارج		5 8		_	6	1	3	6	01/05/99	Au-Young		RE	CFIAE	: <u> </u>	
+			6		0		3	8	0	03/27/01	Billing-Medel et al.		10	N 2 2 200	3	
+			 	3	3	5	1	7	0	01/01/02	Orntoft					
$ abla_{b}$	most -		09		7	0	6	7	+	09/27/00	Feinstein and Mor	170	TEGHU	NTER 1800/2900		
<u>)' '</u>	<u> </u>	L	021		Ľ	<u> ~</u>	ــــــــــــــــــــــــــــــــــــــ			FOREIGN	PATENT DOCUMI	ENTS				
	. 4.		n	oci	ımı	ment Num			ıber	Date	Country	Class	Subclass	Trans		
				-			-							Yes	No	
W	201	wo	6	1	<u>b</u>	2	8	6	4	04/05/01	PCT					
<u> ۱۲</u>	<u> </u>	<u> </u>	Δ	rh	ER	D	$\overline{\alpha}$	CUN	ИE	NTS (Inclu	ding Author, Title, D	ate, Perti	nent Pages,	Etc.)		
731	21	1	T_		#T	2100	140	- 0	anc	er " Curr. C	Opin. Oncol. 10(3):273	3-278 (199	(8)			
ועי		Ozen, "Bladder Cancer," Curr. Opin. Oncol. 10(3):273-278 (1998) Torti and Lum, "The Biology and Treatment of Superficial Bladder Cancer," J. Clin. Oncol.														
	~	0.65 505 521 (1094)														
1	-	Grossman, "New Methods for Detection of Bladder Cancer," Semin. Urol. Oncol. 16(1):17-22														
	-	Sarver et al. "Exploring Catalytic RNAs (Roibozymes) as Anti-HIV Agents," pp. 303-323 in														
	+	Culver, "Site-Directed recombinant for repair of mutations in the number ADA gene, (1998)														
	<u> </u>										c co in o b	inh_rick ni	กทายสมเดม ดูมา	patients wit	h	
	4	Lacombe et al., "Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy; correlation to clinical outcome," J. Urol. 153(3) Part 1:564-572 (1995) Herskowitz "Functional inactivation of genes by dominant negative mutations" Nature 329: 219														
	1.	1	H	ers	sko	wit	z ")	Fun	cti	onal inactiva	tion of genes by domi	nant nega				
n	PD	十	F	lud	sor	ı ar	ıd I	Her	r, "	Carcinoma	in situ of the bladder,"	J. Urol.	153(3) Part 1	:304-3/2 (1772)	
EXA	MÍN	ER	,	5	ζ					DATE CO	NSIDERED (0) 9	03				
*KX	ر (AMI	NER	: In	tial	if r	efer	renc	e-co	nsi	lered, whether	or not citation is in confo	rmance with	ı MPEP 609: D	raw line thro	ugn cita	
not	in co	nforn	anc	e an	nd n	ot c	ons	ider	ed.	Include copy of	of this form with next com	municanon (- abb			

Applicants: Elena Feinstein and Orna Mor U.S. Serial No.:09/825,682 Filed: April 4, 2001
Title: SEQUENCES CHARACTERISTIC OF
BLADDER CANCER
Exhibit A

Pale B.	ŢO-1	1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 65503-B	Serial No. 09/825,6 22
212	13 . 155.	INFORMATION DISCLOSURE CITATION	Applicants Elena Feinstein an	d Orna Mor
	اً عجد ا	BY APPLICANT (Use several sheets if necessary)	Filing Date April 4, 2001	Group 🛱 松
MOE		OTHER DOCUMENTS (Including Author, Tit	le, Date, Pertinent Page	es, Etc.)
M),[Rosenthal et al., "Human bladder tumour cDNA li	brary derived EST 15", 00	Geneseq03802
	-	National Institutes of Health, Mammalian Gene Co	ollection, "Homo sapiens	6
	,	Quark Biotech Inc., "Bladder cancer-associated sec	quence, TCC75E3", Ger	
	1	Quark Biotech Inc., "Bladder cancer-associated seconds A \$ \$01297 submitted July 2001		
M		Billing-Medel et al., "Sequence 7 from patent US AR139477, submitted June 2001	6207380", GeneEmbl A	ccession No.
	\dashv			
	-			
EXAM				
1)	NATINI	ER: Initial if reference considered, whether or not citation is not in conformance and not considered. Include copy of this i	in conformance with MPE	P 609: Draw line through